$25 Million is the figure hanging in the balance as Connecticut lawmakers prepare to vote on a long-debated expansion of the state’s research and development (R&D) tax credit. On Thursday, the Commerce Committee will consider House Bill 5319, a proposal to extend these credits to businesses with under $70 million in gross income – a move that, while seemingly modest in scale, represents a significant shift in how Connecticut incentivizes innovation and a direct response to competitive pressures from neighboring states. Follow the money, and you’ll find this isn’t simply about tax breaks; it’s about retaining a crucial segment of the state’s economy and ensuring small businesses can participate in Connecticut’s ambitions in high-growth sectors like biotech and advanced manufacturing.
For years, Connecticut’s R&D tax credit has been largely inaccessible to the state’s most numerous businesses – the pass-through entities that don’t pay corporate taxes. These companies, whose owners report business income on their personal taxes, have been effectively penalized for their structure, unable to leverage the same incentives as larger corporations. This disparity has fueled frustration among small business owners and created a two-tiered system that industry groups argue stifles innovation. “Any time that we don’t have this type of incentive for businesses to do this type of activity here, you run the risk of them doing it in a more cost-effective state,” explained Chris Davis, vice president of public policy for the Connecticut Business and Industry Association, highlighting the risk of businesses relocating to states with more favorable tax policies. The proposed voucher program, capped at $25 million annually and offering a 6% credit on R&D expenses (with a $1.5 million per-company limit), aims to level the playing field.
The timing of this renewed push is critical. While Connecticut has made strides in attracting investment in sectors like biotechnology – boasting over 24,000 life sciences employees contributing $7 billion to the state’s GDP – many of these companies are small and reliant on external funding. Jodie Gillon, president and CEO of BioCT, emphasized the need to nurture these emerging companies, stating, “Connecticut is primarily a startup state…We just want to make sure that, as our companies are evolving, they keep their footprint in Connecticut.” The proposed bill recognizes this dynamic, offering a higher reimbursement rate – 90% instead of 65% – for biotech companies, signaling a strategic prioritization of this key industry. This isn’t simply altruism; it’s a calculated investment in a sector poised for significant growth, particularly given the state’s proximity to leading research institutions.
However, the path forward isn’t without its complexities. Past attempts to expand the R&D credit have stalled, largely due to concerns about the potential cost to the state. While the current proposal is designed to mitigate this risk – operating within the state’s volatility cap – questions remain about whether the credit will genuinely stimulate new economic activity or simply subsidize projects already in the pipeline. Rep. Stephen Meskers, co-Chair of the Commerce Committee, acknowledged this tension, noting the ongoing debate about “how much steering you want to be involved in” with tax policy. This echoes broader concerns about the effectiveness of state R&D credits, as highlighted by Alison Wakefield of the Pew Charitable Trusts, who points to the lack of consistent evidence demonstrating a clear link between these incentives and increased innovation.
Original reporting: ctmirror.org.
The debate over H.B. 5319 isn’t just about dollars and cents; it’s about Connecticut’s long-term economic strategy. The state is actively courting investment in high-tech industries, but without a supportive tax environment for small businesses, it risks losing out to competitors like New York and Massachusetts, which have already made significant R&D investments. The federal landscape adds another layer of uncertainty, with potential cuts to federal research funding creating a need for states to step up and fill the gap. The proposed bill, with its targeted approach and financial safeguards, represents a pragmatic attempt to address these challenges.
What this means for your wallet: If H.B. 5319 passes, expect to see increased investment in R&D within Connecticut’s small business sector, potentially leading to job creation and the development of new technologies. But more importantly, watch whether the state’s biotech and advanced manufacturing industries experience a noticeable uptick in activity – and whether this translates into a broader economic benefit for all Connecticut residents. The key question isn’t just if the credit is approved, but how effectively it’s implemented and whether it truly delivers on its promise of fostering a more vibrant and innovative economy.
